Connor Clark & Lunn Investment Management Ltd. Takes $466,000 Position in Krystal Biotech, Inc. $KRYS

Key Points

• Connor Clark & Lunn Investment Management Ltd. has acquired a new stake in Krystal Biotech, purchasing 2,582 shares valued at approximately $466,000 during the first quarter.
• Several institutional investors, including Fifth Third Bancorp and GAMMA Investing LLC, have significantly increased their positions in the company, indicating growing interest in Krystal Biotech.
• Wall Street analysts have a generally positive outlook on the stock, with an average rating of "Buy" and an average price target of $210.75, reflecting confidence in the company's growth prospects.

Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,582 shares of the company's stock, valued at approximately $466,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Crossmark Global Holdings Inc. boosted its position in shares of Krystal Biotech by 2.7% during the 1st quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company's stock valued at $427,000 after acquiring an additional 63 shares during the last quarter. Xponance Inc. lifted its position in Krystal Biotech by 4.9% in the 1st quarter. Xponance Inc. now owns 1,873 shares of the company's stock worth $338,000 after buying an additional 88 shares during the last quarter. Sound View Wealth Advisors Group LLC lifted its position in Krystal Biotech by 6.7% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 1,515 shares of the company's stock worth $273,000 after buying an additional 95 shares during the last quarter. New York State Teachers Retirement System lifted its position in Krystal Biotech by 0.6% in the 1st quarter. New York State Teachers Retirement System now owns 15,979 shares of the company's stock worth $2,881,000 after buying an additional 100 shares during the last quarter. Finally, Fifth Third Bancorp lifted its position in Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after buying an additional 105 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Krystal Biotech Trading Up 3.3%

KRYS stock traded up $4.79 during midday trading on Friday, hitting $150.49. The company had a trading volume of 246,954 shares, compared to its average volume of 428,473. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $207.84. The stock's 50 day moving average price is $144.22 and its 200 day moving average price is $154.55. The stock has a market cap of $4.36 billion, a price-to-earnings ratio of 30.59 and a beta of 0.70.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The firm had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. Analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 1,389 shares of the business's stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the transaction, the insider directly owned 1,508,056 shares of the company's stock, valued at approximately $226,208,400. The trade was a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 49,800 shares of company stock valued at $7,487,943 in the last ninety days. Insiders own 13.70% of the company's stock.

Analyst Ratings Changes

KRYS has been the subject of a number of recent research reports. Bank of America dropped their target price on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. HC Wainwright restated a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a research report on Friday. Chardan Capital dropped their target price on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a research report on Friday. Citigroup restated a "neutral" rating and issued a $166.00 target price (down previously from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. Finally, Guggenheim dropped their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, Krystal Biotech currently has a consensus rating of "Buy" and an average target price of $210.38.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).